Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript

Compass Pathways (NASDAQ: CMPS ) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Compass Pathways reported significant progress in the first half of 2026, with positive Phase 3 trial results for COMP360, indicating rapid onset and sustained effects in treating treatment-resistant depression (TRD).

The company is advancing its New Drug Application (NDA) for COMP360, expecting to complete the filing in Q4 2026, with a potential accelerated approval. Compass Pathways has $433 million in cash, sufficient to support operations through the launch and into 2028, and is building a strong commercial team to prepare for the product launch. Strategic collaborations with Radial and Osmind are enhancing the company's readiness to ensure optimal site and patient experience at launch. Operational plans include training and preparing interventional psychiatry sites, leveraging existing infrastructure to support COMP360’s unique treatment requirements.

The company is engaging with payers for reimbursement strategies and preparing a field reimbursement team for product launch. Future strategic priorities include focusing on the PTSD study and exploring other potential indications for COMP360 post-launch. Full Transcript OPERATOR Good day, ladies and gentlemen, and welcome to the Compass Pathways second quarter 2026 conference call. At this time, all participants are in listen-only mode.

As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Stephen Schultz. You may begin. Steve Schultz, Senior Vice President, Investor Relations Thank you, operator.

I welcome all of you and thank you for joining us today for this conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways, and today I'm joined by Kabir Nath, our Chief Executive Officer, and Laurie Engelbert, our Chief Commercial Officer. Terry Luxem, our Chief Financial Officer, will also be available for the Q&A. The call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call and will be available for a period of 30 days.

Before we begin, let me remind everyone that during the call today, we will be making statements about our future plans and prospects that constitute forward-looking statements. S. Securities and Exchange Commission. These forward-looking statements represent our views only as of today and we specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change.

I'll now hand the call to Kabir Nath. Kabir Nath, Chief Executive Officer Thank you, Steve, and thank you all for joining us today. The first half of this year has been an exciting time for Compass. Now that we have highly statistically significant, positive Phase 3 primary endpoint readouts, as well as demonstrated durability through six months from both our trials, we believe we have largely de-risked the clinical and regulatory profile of COMP360.

In addition to confirming its rapid onset and durability, the totality of data from the program so far shows it has a generally well-tolerated and safe profile. Taken together, these data reinforce our belief that COMP360 has the potential to fundamentally change how mental health is managed. With these data sets in hand, we continue to make significant progress towards our NDA filing for the treatment of TRD. Our rolling submission and review process allows us to submit data in waves to the FDA, and they have started to review some modules that we've already submitted.

We continue to expect to complete the NDA filing in the fourth quarter, with the potential for an accelerated approval following our final submission. We are advancing our commercial readiness. We built a fantastic commercial team with incredible experience, and we're executing on all fronts to be prepared to get COMP360 to the millions of patients living with TRD who urgently need new treatment options. We're also well positioned with our strong balance sheet, with $433 million of cash on hand as of June 30, which carries us well through launch and into 2028.

Let me now hand the call to Laurie to talk through, in more detail, how we're preparing to transform treatment options for these patients. Laurie Engelbert, Chief Commercial Officer Thanks, Kabir. Hi everyone, thank you for joining. As Kabir outlined, we have achieved significant milestones in the first half of the year, notably advanced important commercial readiness initiatives across organizational capabilities, strategic collaboration, policy and payer engagement, and distribution — all significant steps towards being launch-ready.

Earlier this year we rounded out hiring of the commercial leadership team, attracting highly experienced, energized leaders who immediately started to build out their functions. My direct reports come from companies like J&J, Gilead, Otsuka, and Axum, and between them have led over 70 product launches. The prospect of launching the first psychedelic in history, with a medicine that has the potential to fundamentally change the way mental health is treated, is a very powerful attractor of talent, and we are bringing in outstanding professionals from across the pharma industry. I am incredibly proud of the team we are building at Compass.

In the first half of this year we also announced additional strategic collaborations with Radial and Osmind, taking the total to eight, each with their own distinct capabilities. These collaborations played a critical role in helping to inform our priority focus at launch of ensuring optimal site and patient experience. With the final submission of our NDA expected in the fourth quarter, our focus in the second half of this year is on operationalizing launch plans and ensuring launch readiness. This includes advancing everything from training, education, access and reimbursement, and patient support mechanisms.

Importantly, we have also already initiated recruiting for the field force. Our timelines for launch remain fluid given the National Priority Review voucher and Executive Order in April and the need for federal DEA and state rescheduling. We remain focused on being ready to launch, which we anticipate being in the first half of 2027. At launch we will leverage the well-established existing interventional psychiatry treatment center infrastructure.

These treatment sites are specifically designed to support in-office treatments for products that require multi-hour monitoring, such as Spravato, TMS, and ECT. The established infrastructure has existing capacity and, importantly, is already equipped with the staff and operational know-how needed to support additional multi-hour treatments like COMP360. Seven years ago when Spravato launched, this infrastructure did not exist. , and this continues to grow rapidly.

COMP360 is poised to lead a profound shift in mental health care, moving beyond daily or frequent dosing toward an option potentially involving just a few treatments a year, which could be life-changing for patients. Across two highly statistically significant and positive Phase 3 trials, COMP360 demonstrated extremely rapid onset of action, with deep and clinically meaningful reduction in depressive symptoms as quickly as one day, unprecedented durability sustained through at least six months, and notably reproducibility of effect in a chronic treatment-resistant patient population — one of the most difficult psychiatric conditions in which to demonstrate efficacy.

The data are strong, and both patients and prescribers are excited about the potential for a new treatment option. In recent prescriber-focused market research, approximately 90% of interventional psychiatrists stated that they would prescribe COMP360 within the first year of being available. In my experience this is the highest willingness-to-prescribe percentage I have ever seen in pre-launch market research.

With the COMP360 emerging profile and continued interest and excitement around the class, we are eager to bring a new treatment option to the 4 million patients living with TRD today who have limited treatment options, and we are confident in the blockbuster opportunity. COMP360 has the potential to fundamentally change the way that patients living with depression are cared for, and Compass is committed to helping as many patients as possible. We are making significant progress towards being launch-ready, and I look forward to discussing more with you throughout the rest of this very exciting year. Thank you, and let me hand the call back to Kabir.

Kabir Nath, Chief Executive Officer Thank you, Laurie. Our progress in the first half of the year has meaningfully de-risked the path towards potential approval and launch and reinforces our confidence in the strength, consistency, and robustness of the COMP360 data package that we are submitting to the FDA. With the regulatory process underway, our focus is on disciplined execution, completing our filing activities, and preparing for a first-pass approval, and ensuring we are poised to deliver COMP360 to patients with TRD as quickly as possible following approval — and as you just heard from Laurie, we will be ready with that.

Let me pass the call to the operator for Q&A. Thank you. OPERATOR We will now begin the question-and-answer session. Please limit yourself to one question.

If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device.

Please stand by while we compile the Q&A roster. Your first question is from the line of Paul Matisse with Stifel. Your line is open. Please go ahead.

Paul Matisse, Analyst at Stifel Hey, good morning. Thanks so much for taking my question. Specifically, I was wondering if the team could offer some perspective on the recently issued FDA guidelines around psychedelics. And more specifically, how did you interpret the discussion of those guidelines as it relates to 12-month blinded durability?

What do you think that really means or what the FDA is asking for? And how do we think about that in the context of the COMP360 program? Thanks so much. Kabir Nath, Chief Executive Officer Thanks, Paul.

I'm just checking you can hear me clearly. Paul Matisse, Analyst at Stifel Yes, yes, thank you. Kabir Nath, Chief Executive Officer Thanks. Yeah, so look, I think, you know, as you're aware, this is a finalization of a set of draft guidelines.

And the original draft in fact came out even after we had fully designed our Phase 3, aligned with the agency on that and so on. So our perspective is we have had very robust, continuing dialogue with the agency throughout this program. And while the guidance is certainly interesting, and we do have thoughts on the 12 months blinded — and that would seem like a pretty tall order for any psychiatry drug — we actually don't think it's going to impact the process of our regulatory approval at this stage.

I think the other parts of that that I'd draw your attention to is the design of Phase 3 studies in a complementary pair continues to be effectively exactly in line with the design of our studies. So while I think the guidance is interesting and obviously, in terms of future endeavors, we will be carefully looking at that, we honestly do not think that these guidelines are going to impact the regulatory process that's already underway for us. Paul Matisse, Analyst at Stifel Great. Thanks so much.

OPERATOR Your next question is from the line of Francois Brisbois with LifeSci Capital. Your line is open. Please go ahead. Francois Brisbois, Analyst at LifeSci Capital Hi, thanks for the question here.

I was just wondering, in terms of launch, can you help us understand — this always happens, but especially in your situation — just the reimbursement challenges. What are we going to have to go through, just to get a better feel for the cadence here, with the launch expected next year? Laurie Engelbert, Chief Commercial Officer Hey, Frank, thanks. A question.

You know, as you mentioned, launches are traditionally hard, you know, coming out of the gate with reimbursement just because you need time. What we are doing now is our market access team is already engaging with payers and they have been now for some time. We're getting very positive feedback from the payers, especially in this TRD patient population, where proving efficacy has almost been impossible to do in the past. So it is playing very well with a key stakeholder who really, truly understands the economic burden that patients with TRD can have on a payer system.

So at launch, what we expect is we are intending to have a field reimbursement team fully deployed at the time of launch, who will be out helping these sites ensure that they can code and get the reimbursement that they need to code for, and making sure that they're well educated in the process in terms of the drug reimbursement. And the conversations we're having with payers right now, we are working through that. We are still ingesting the data that we just got and released a couple weeks ago into the value proposition that COMP360 can bring.

And then we'll make decisions as we get closer to launch on what that might look like in terms of rebating and payer negotiations for formulary access. OPERATOR Your next question is from the line of Gavin Clark-Gartner with Evercore. Your line is now open. Please go ahead.

Gavin Clark-Gartner, Analyst at Evercore ISI Hey, guys, congrats on the progress. Thanks for taking the question. Maybe you could just characterize how any ongoing regulatory discussions are progressing. And separately, what are your expectations for DEA scheduling timelines at this point?

Thank you. Kabir Nath, Chief Executive Officer Thanks, Gavin. So on the first part, I would just say they're going well. I mean, the rolling submission is well underway.

As I noted in the remarks, some of what has been sent is under review. We're getting questions on it. Clearly, given the acceleration, given the NPV, the onus is also on us to respond very quickly, and we're doing that. So the team is doing an amazing job of being responsive to that.

So nothing out of the ordinary that I would say; we remain on track. And as you know, it's only in the later stages that things like label and REMS really come into play. Those are typically negotiated fairly late in the day. So nothing untoward to report, except we're very happy with progress on rescheduling.

I'll hand to Ari. OPERATOR Your next question is from the line of Ritu Baral with TD Cowen. Your line is now open. Please go ahead.

Ritu Baral, Analyst at TD Cowen Good morning, guys. Thanks for taking the question. Another question for you, Laurie, specifically around the term training that you used in the prepared remarks. It sounds like, in response to some of the prior questions, some of that training for the interventional psychiatry sites will revolve around coding.

But I wanted to ask what other aspects of training does the team plan on offering interventional psychiatry sites, especially given that you have a very solid precedent REMS to sort of train against and anticipate. How do you anticipate offering sort of readiness services to those sites and how does that impact, I think, how all of us may model 2027 rollout? We've here at TD Cowen had experience with sponsors really wanting to manage the early experience with a drug at sites and with clinicians on early rollout. So anything you can tell us about sort of the general shape of 2027 as you see it now with the training offered?

Thanks. Laurie Engelbert, Chief Commercial Officer Yeah, hey Ritu, thanks for the question. I'm going to try and collect it all into one cohesive thought. So the way I think about training — you're brilliant at this — you know, we think about training, we think about training in two parts.

So there's going to be training and there'll be education. So I will address both. But in terms of training, and specifically training, you know, we announced a little while ago that we are participating in grants for third-party companies to help with the training of the site both on psychedelics, and as soon as COMP360 gets a final label on anything that's required for the monitoring time that the patient will be in the room, we want to make sure that that patient experience is a very good one, and so we are still doing that. So the sites will need to be trained because in the REMS they will need to attest to being trained.

And part of that will be based on the training that these third-party providers are enabling. Already there are well over 1,000 people who are already trained on the psychedelic portion of that training, and so there is a broader group of people already ready to go with that training. The other training — again, the COMP360 piece of that particular training on how to best support a patient and help enable a very good patient experience — that will come after we see the final label and we get that finalized. We also will need to do training on REMS to make sure that they are compliant with REMS certification and all the things that they need to do with REMS.